6
NEWS
OP5OP5
C-19 T1D risk in kids
Children with presymptomatic Type 1 diabetes progress more quickly to Type 1 diabetes after having Covid-19,
according to a research letter published in JAMA.
In an analysis of data from 509 children who were positive for two or more islet autoantibodies linked to Type 1
diabetes, rates of Type 1 diabetes diagnoses increased after the onset of the Covid-19 pandemic, compared with before
the pandemic. Of children who developed Type 1 diabetes during the pandemic, incidence rates were higher for those
who had Covid-19 than for children who tested negative for Covid-19.
"Future research should discover the mechanisms by which infection with viruses such as SARS-CoV-2 can change
the course of Type 1 diabetes and to determine whether protection against infection helps," said Anette-Gabriele
Ziegler, MD, director of the Institute of Diabetes Research at Helmholtz Munich, German Research Center for
Environmental Health.
Watch out!
Direct-to-watch integration to
strengthen Dexcom's position
in wearable health technology,
says GlobalData, a London-based
industry-specific intelligence
platform.
The Covid-19 pandemic
acted as a catalyst for the rapid
implementation and development of
wearable technology in the medical
market. Wearable technologies,
such as smartwatches and medicalgrade
wearables, have emerged as
indispensable tools for remotely
tracking glucose levels and managing
diabetes. Following the wearable
trend in medical, the recent update
enables Apple Watch users to
display glucose data directly from
older Dexcom Continuous Glucose
Monitoring (CGM) devices. The move
is expected to cement Dexcom's
position in the wearable health
technology space, says the company,
which is a leading data and analytics
company.
Kamilla Kan, Senior Data Scientist,
Medical Devices team at GlobalData,
comments: "The market is poised
for growth, driven by increased sales
of hearables and smartwatches.
Moreover, the integration of artificial
intelligence (AI) holds the potential
to inaugurate a new era of interactive
and intelligent wearable devices,
thereby enhancing user experiences."
Previously, Apple Watch
users relied on iPhones to relay
glucose data from Dexcom CGMs,
resulting in potential delays and
incomplete information due to
Apple's restrictions on third-party
app refresh rates. However, with the
latest update, Dexcom G7 adds to the
user experience by enabling direct
Bluetooth connectivity between the
CGM, smartphone, pump, and Apple
Watch, allowing for real-time glucose
monitoring directly on the wrist.
Kan concludes, "The pandemic
has propelled the adoption of these
technologies among healthcare
professionals and patients alike,
paving the way for a more connected
and proactive approach to diabetes
management both during and
beyond the pandemic. With both
Dexcom and Abbott securing FDA
clearances for over-the-counter
CGMs in the US, the competition
in the glucose monitoring market
intensifies. However, Dexcom's
strategic investment in direct-towatch
integration demonstrates
its commitment to innovation and
user-centric design, positioning the
company as a leader in the evolving
landscape of wearable health
technology."
www.dexcom.
what image?
CeQur's FDA
nod
CeQur has announced recently
that the FDA has granted 510(k)
clearance for its Simplicity system
for an extended wear duration.
Simplicity, a wearable, disposable
bolus insulin delivery system,
was developed as, essentially, a
wearable insulin pen.
Clearance extends the wear
time for the wearable mealtime
insulin delivery patch from
three to four days. It marks a
significant advancement for
what the company claims is
the longest wearable insulin
delivery patch, which provides
diabetes discretion, additional
convenience and injection-free
dosing. Each patch now replaces
up to 12 mealtime injections,
equalling more than 1,000 fewer
injections annually, according to a
news release.